FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia Topline data from 1-year open-label extension (OLE) long-term safety trial expected in Q4 2024 CUPERTINO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:... Read More